



TM

Zensar Technologies

10 June 2024

Margin expansion in FY24; revenue growth focus for FY25

COMPANY UPDATE

Sector: IT & ITES Rating: NOT RATED

CMP: Rs 673 Target Price: NA

Stock Info

Sensex/Nifty	76,693/23,290
Bloomberg	ZENT IN
Equity shares (mn)	227
52-wk High/Low	697 / 376
Face value	Rs 2
M-Cap	Rs 152.5bn/USD 1.84bn
3-m Avg turnover	USD 10.08mn


Financial Snapshot (Rs mn)

Y/E Mar	FY22	FY23	FY24
Net sales	42,438	48,482	49,019
EBITDA	6,566	5,522	8,718
EBITDA (%)	15.5%	11.4%	17.8%
PAT	4,217	3,276	6,651
EPS	18.7	14.5	29.4
P/E (x)	36.5	46.5	22.9
P/B (x)	5.7	5.1	4.3
EV/EBITDA (x)	22.1	25.9	16.2
RoE (%)	16.6%	11.6%	20.3%
RoCE (%)	16.6%	11.8%	20.9%

Shareholding Pattern (%)

	Mar'24	Dec'23	Sep'23
Promoter	49.2	49.2	49.2
- Pledged	-	-	-
FII	16.5	17.1	16.7
DII	17.5	16.5	16.6
Others	16.8	17.2	17.6

Stock Performance (1-year)



We met the management of Zensar Technologies (ZENT IN) as a part of RPG group investor day. The company's EBITDA margin improved in FY24 by more than 600bps to 17.8% as the company i) reduced its subcon costs, ii) lowered backfilling employee costs as attrition moderated, and iii) cut tail accounts with lower profitability. However, FY24 revenue growth was muted. For FY25, the company expects revenue growth to revive as; i) it is targeting large deals (USD 25mn+) in each vertical and each geography during this period, ii) it expects to focus on the Gaming sub-vertical for growth (which comes under Hi-Tech vertical), and iii) is looking for an acquisition in healthcare vertical. The company witnessed sequential growth in all 4 verticals in 4QFY24 after several quarters and expects this momentum to sustain in FY25. Management indicated it is not looking to add any more verticals at this stage, as existing verticals present enough organic and inorganic opportunities. Management sees Generative AI as a technology to be used more as an automation tool due to lack of any earth-shattering use cases so far. We do not have a rating on the stock, which currently trades at 23.4x 1-year-forward PE multiple.

Geographical and vertical FY24 financial performance in USD terms: For FY24, the company reported 1.6% YoY revenue decline in CC terms and 2% decline in USD terms. While US (67% of mix) revenue fell 6.8% YoY, Europe and Africa (33%) reported 12.7% and 5% YoY revenue growth, respectively, in USD terms. Vertical-wise, Banking & Financial Services and Manufacturing & Consumer Services grew by 7.7% and 0.8% YoY, whereas Healthcare & Hi-Tech fell by 5.9% and 13.7% YoY, respectively. EBITDA margin improved 640 bps to 17.8% in FY24.

Gaming – a differentiating factor: ZENT has also been strengthening its capabilities in the gaming industry. It provides gaming solutions to one of the largest gaming conglomerates in the world that controls over 40% of the industry. ZENT offers a wide range of solutions like adapting games from one country to another, testing, character creation, engineering, and content creation, in addition to introducing these to the market in a structured way. Management sees Gaming as growth lever, as it believes this is a rapidly growing niche segment in which it has the expertise in content, that could differentiate it from competition. Currently, the company has a staff of 500 at its offshore development center (ODC) for this segment. The gaming segment requires a unique mix of content, engineering, and data skills and the big players may not be interested due to i) lack of skillsets, and ii) lower deal sizes.

Healthcare – Exploring acquisitions for growth: The vertical currently forms ~10% of its revenue mix. ZENT reported 3%+ QoQ growth in this vertical after muted growth in the last few quarters, as this was the first full quarter where the company has a leader in this space. The company has clearly identified sub-industries in this vertical on which it wishes to focus. It is also looking for an acquisition in this vertical for growth.

Generative AI: ZENT believes the biggest risk in Generative AI is that it may not turn out as per the hype in the market. It is of the view that the technology is currently being used as an automation tool globally, as statistics which work on smaller data sets may not give accurate results on larger /complex data sets. Therefore, currently, the usage is limited to use cases like creating chatbots for answering queries or providing summaries of documents that run into thousands of pages, etc. The industry is yet to come up with earth-shattering use cases, thereby limiting its usage.


Sameer Pardikar
sameerpardikar@systematixgroup.in
+91 22 6704 8041

Devanshi Kamdar
devanshikamdar@systematixgroup.in
+91 22 6704 8098

Other highlights


- In FY25, the company expects to focus on winning large deals, and delivering value through people excellence, apart from engaging in more managed services work and increasing their annuity revenues. Management highlighted that generally there is a **tradeoff** between achieving revenue and margin growth and it needs to constantly find the optimum balance that maximizes both. In FY24, the company saw more opportunities on the margin front, than in revenue growth, which explains its significant ramped up in margins (11.4% in FY23 to 17.8% in FY24). However, this year, management expects margins to range in the narrow band of 15%-16%, as investments in sales may go up towards chasing large deals.
- The company began experimenting with **true verticalization model** in their **BFSI** vertical 2 years ago, and it turned out to be successful. The true verticalization model involves focusing on enhancing domain capabilities by aggregating accounts and optimizing the 3 pillars - People, Process and Technology. To achieve this, the company has formed a 'Domain Consulting Group' that continuously works on adding and enhancing vertical specific capabilities to deliver excellence to clients. They have fully implemented this model in the BFSI vertical, progressed significantly in the Manufacturing and Consumer services vertical, but are a little behind in the Hi-Tech vertical and are starting from scratch in the Healthcare and Lifesciences vertical.
- Last year, the company put up a formal **account management system** that focused on building deeper relationships with larger clients, with the aim of mining them further.
- The company has been conservative its **Book to Bill ratio** at 1-1.2x compared to the industry. This ratio, management believes, could reduce if larger deals with higher tenures come in as annuity revenue
- After COVID, **discretionary spending** shot up due to the rapid digital transformation, causing global companies' valuations to surge. The same has been moderating over the last 2 years. Currently, GenAI and chip manufacturers are in focus. Here, the hyper-scalers are expected to integrate AI and System Integrators (SIs) like ZENT are expected to come into the picture and assist in implementing the same. Hence, there is some opportunity to scale up in this area.
- Last year, the company introduced its **"Start Green, Stay Green, & Close Green"** initiative, through which it focused on staying profitable throughout the client life cycle. The company refrained from taking up large deals with negative margins. The end goal was to build organizational muscle for executing large deals and take a quantitative approach to **risk management**, which would help them in identifying issues at an early stage.
- Following are the 3 areas where the company operates in terms of AI:
 - **AI Engineering Buddy** – This tool helps organizations in reducing their tech debt.
 - **AI Data Buddy** – This tool offers a bunch of solutions for getting the data ready for generative AI.
 - **AI Ignite** – This is a tool introduced to upskill ZENT employees and make them AI ready.

Exhibit 1: US revenue trend




Source: Company, Systematix Institutional Research

Exhibit 2: Europe revenue trend




Source: Company, Systematix Institutional Research

Exhibit 3: Africa revenue trend




Source: Company, Systematix Institutional Research

Exhibit 4: BFSI revenue trend




Source: Company, Systematix Institutional Research

Exhibit 5: Hi-Tech revenue trend




Source: Company, Systematix Institutional Research

Exhibit 6: Retail revenue trend




Source: Company, Systematix Institutional Research

Exhibit 7: Healthcare revenue trend




Source: Company, Systematix Institutional Research

Exhibit 8: Top 5 clients revenue trend




Source: Company, Systematix Institutional Research

Exhibit 9: Top 10 clients revenue trend




Source: Company, Systematix Institutional Research

Exhibit 10: Top 20 clients revenue trend




Source: Company, Systematix Institutional Research

Exhibit 11: EBITDA margin trend



Source: Company, Systematix Institutional Research

Exhibit 12: Utilization trend



Source: Company, Systematix Institutional Research

FINANCIALS

Profit & Loss Statement

YE: Mar (Rs mn)	FY21	FY22	FY23	FY24
Revenue	36,682	42,438	48,482	49,019
Employee expenses	24,417	29,213	35,000	33,433
Other expenses	5,422	6,659	7,960	6,868
EBITDA	6,843	6,566	5,522	8,718
EBITDA margin	18.7%	15.5%	11.4%	17.8%
Depreciation	1,733	1,848	1,830	1,338
EBIT	5,110	4,718	3,692	7,380
EBIT margin	13.9%	11.1%	7.6%	15.1%
Interest expense	535	353	279	209
Other income	255	1,377	1,028	1,588
Exceptional item loss/(gain)	-	-	-	-
Profit before tax	4,830	5,742	4,441	8,759
Taxes	1,262	1,525	1,165	2,108
Tax rate	26.1%	26.6%	26.2%	24.1%
PAT	3,568	4,217	3,276	6,651
EPS	15.8	18.7	14.5	29.4

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs mn)	FY21	FY22	FY23	FY24
Equity Share Capital	451	452	453	453
Reserves & Surplus (Ex OCI)	22,972	26,417	29,309	35,166
Net worth	23,423	26,869	29,762	35,619
Deferred Tax Liability	-	-	-	-
Long term debt	-	-	-	-
Trade payables	2,201	3,164	2,772	3,095
Other Provisions	32	37	42	48
Other liabilities	8,390	8,325	8,634	7,716
Minority Interest	288	-	-	-
Total Liabilities	34,334	38,395	41,210	46,478
Net block	3,885	3,822	3,262	2,290
Goodwill/Intangible assets	7,445	8,729	8,473	8,103
Other Non-current asset	1,536	1,621	1,814	2,567
Investments	5,173	3,241	8,986	14,083
Cash and Cash Equivalents	3,492	5,054	4,744	4,432
Bank balances other than above	3,494	3,505	2,536	2,809
Debtors	5,888	7,967	7,298	7,320
Other current asset	3,421	4,456	4,097	4,874
Total Assets	34,334	38,395	41,210	46,478

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY21	FY22	FY23	FY24
PBT	4,830	5,742	4,441	8,759
Exceptional Item	-	-	-	-
Depreciation	1,733	1,848	1,830	1,338
Interest	535	353	279	209
Others	-256	-651	-595	-1,077
Operating Profit				
before WC Changes	6,842	7,292	5,955	9,229
Change in WC	-3,148	2,428	-2,113	481
Others including taxes	1,400	1,517	925	2,327
Operating Cash-Flow	8,590	3,347	7,143	6,421
Capex	395	568	368	164
Free cash-flow	8,195	2,779	6,775	6,257
Fin Investments	1,996	-2,068	5,236	4,143
Misc. Items (CFI + CFF)	4,669	1,826	2,186	1,971
Net Δ in cash	1,530	3,021	(647)	143

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY21	FY22	FY23	FY24
Revenue growth	-8.5%	15.7%	14.2%	1.1%
EBITDA (%)	18.7%	15.5%	11.4%	17.8%
RoCE	18.8%	16.6%	11.8%	20.9%
RoNW	15.8%	16.6%	11.6%	20.3%
EPS (Rs)	15.8	18.7	14.5	29.4
DPS (Rs)	-	-	-	-
BVPS (Rs)	104	119	131	157
Debtor days	59	69	55	55
Creditor days	22	27	21	23
P/E (x)	43	37	47	23
P/B (x)	6	6	5	4
EV/EBITDA (x)	21	22	26	16

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
--------------------------	--------------------------	-------------------------	----------------------------------

Equity Research

Analysts	Industry Sectors	Desk-Phone	E-mail
Dhananjay Sinha	Co Head of Equities & Head of Research - Strategy & Economics	+91-22-6704 8095	dhananjaysinha@systematixgroup.in
Abhishek Mathur	FMCG	+91-22-6704 8059	abhishekmathur@systematixgroup.in
Ashish Poddar	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8039	ashishpoddar@systematixgroup.in
Himanshu Nayyar	Consumer Staples & Discretionary	+91-22-6704 8079	himanshunayyar@systematixgroup.in
Manjith Nair	Banking, Insurance	+91-22-6704 8065	manjithnair@systematixgroup.in
Pradeep Agrawal	NBFCs & Diversified Financials	+91-22-6704 8024	pradeepagrawal@systematixgroup.in
Pratik Tholiya	Specialty & Agro Chem, Fertilisers, Sugar, Textiles and Select Midcaps	+91-22-6704 8028	pratiktholiya@systematixgroup.in
Sameer Pardikar	IT & ITES	+91-22-6704 8041	sameerpardikar@systematixgroup.in
Santosh Yellapu	Capital Goods	+91-22-6704 8094	santoshiyellapu@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Sudeep Anand	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8085	sudeepanand@systematixgroup.in
Vishal Manchanda	Pharmaceuticals and Healthcare	+91-22-6704 8064	vishalmanchanda@systematixgroup.in
Chetan Mahadik	Consumer Staples & Discretionary	+91-22-6704 8091	chetanmahadik@systematixgroup.in
Deeksha Bhardwaj	Strategy & Economics	+91-22-6704 8017	deekshabhardwaj@systematixgroup.in
Devanshi Kamdar	IT & ITES	+91-22-6704 8098	devanshikamdar@systematixgroup.in
Hinal Kothari	Metals & Mining	+91-22-6704 8076	hinalkothari@systematixgroup.in
Jennisa Popat	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8066	jennisapopat@systematixgroup.in
Kalash Jain	Midcaps	+91-22-6704 8038	kalashjain@systematixgroup.in
Krishna Zaveri	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8023	krishnazaveri@systematixgroup.in
Mahek Shah	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8040	mahekshah@systematixgroup.in
Nirali Chheda	Banking, Insurance	+91-22-6704 8019	niralichheda@systematixgroup.in
Pashmi Chheda	Banking, Insurance	+91-22-6704 8063	pashmichheda@systematixgroup.in
Pravin Mule	NBFCs & Diversified Financials	+91-22-6704 8034	pravinmule@systematixgroup.in
Prathmesh Kamath	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8022	prathmeshkamath@systematixgroup.in
Purvi Mundhra	Macro-Strategy	+91-22-6704 8078	purvimundhra@systematixgroup.in
Rajesh Mudaliar	Consumer Staples & Discretionary	+91-22-6704 8084	rajeshmudaliar@systematixgroup.in
Ronak Dhruv	NBFCs & Diversified Financials	+91-22-6704 8045	ronakdhruv@systematixgroup.in
Rushank Mody	Pharmaceuticals and Healthcare	+91-22-6704 8046	rushankmody@systematixgroup.in
Swati Saboo	Midcaps	+91-22-6704 8043	swatisaboo@systematixgroup.in
Vivek Mane	Pharmaceuticals and Healthcare	+91-22-6704 8046	vivekmane@systematixgroup.in
Yogeeta Rathod	Midcaps	+91-22-6704 8081	yogeetarathod@systematixgroup.in

Equity Sales & Trading

Name		Desk-Phone	E-mail
Vipul Sanghvi	Co Head of Equities & Head of Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Jignesh Desai	Sales	+91-22-6704 8068	jigneshdesai@systematixgroup.in
Sidharth Agrawal	Sales	+91-22-6704 8090	sidharthagrawal@systematixgroup.in
Shreya Chaudhary	Sales	+91-22-6704 8033	shreyachaudhary@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8003	rahul@systematixgroup.in
Chintan Shah	Sales	+91-22-6704 8061	chintanshah@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Karan Damani	Sales Trading	+91-22-6704 8053	karandamani@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8087	vipulchheda@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Rahul Singh	Dealer	+91-22-6704 8054	rahulsingh@systematixgroup.in
Niraj Singh	Dealer	+91-22-6704 8096	nirajsingh@systematixgroup.in

Corporate Access

Mrunal Pawar	Vice President & Head Corporate Access	+91-22-6704 8088	mrunalpawar@systematixgroup.in
Darsha Hiwrale	Associate Corporate Access	+91-22-6704 8083	darshahiwrale@systematixgroup.in

Production

Madhu Narayanan	Editor	+91-22-6704 8071	madhunarayanan@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in

Operations

Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Hiren Patel	Assistant Manager	+91-22-6704 8056	hirenpatel@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Sameer Pardikar, Devanshi Kamdar**, hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. **ISSUER SPECIFIC REGULATORY DISCLOSURES**, unless specifically mentioned in point no. 9 below:

- The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

II. **DISCLAIMER**

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917